Seminars in Oncology
Volume 33, Issue 5 , Pages 614-624 , October 2006

Vaccines in Renal Cell Carcinoma

  • Hubert Kübler
    • ,
  • Johannes Vieweg

      Affiliations

    • J.V. is receiving research support from Geron Corporation. He has acted as a consultant for Argos Therapeutics, Geron Corporation, Novartis Pharmaceuticals Corporation, and GlaxoSmithKline.
    • Corresponding Author InformationAddress correspondence to Johannes Vieweg, MD, Department of Urology, University of Florida, College of Medicine, Room N2-3, Health Science Center, PO Box 100247, Gainesville, FL 32610-0247, USA.

References 

  1. Vieweg J, Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther. 2004;4:1791–1801
  2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  3. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest. 2002;109:1519–1526
  4. Greenberg PD, Riddell SR. Deficient cellular immunity—Finding and fixing the defects. Science. 1999;285:546–551
  5. Finke JH, Tubbs R, Connelly B, et al. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann NY Acad Sci. 1988;532:387–394
  6. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–213
  7. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–18543
  8. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798–3807
  9. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol. 1996;24:859–862
  10. Su Z, Vieweg J, Weizer AZ, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 2002;62:5041–5048
  11. Slingluff CL, Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med. 2005;3:18
  12. Wing K, Ekmark A, Karlsson H, et al. Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology. 2002;106:190–199
  13. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 2003;112:1310–1312
  14. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988
  15. Derweesh IH, Tannenbaum CS, Rayman PA, et al. Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat Res. 2003;116:29–51
  16. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1995;41:111–121
  17. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer. 1995;61:780–785
  18. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213–1222
  19. Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159:4772–4780
  20. Dillman R, Barth N, Vandermolen L, et al. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004;19:570–580
  21. McCune CS, O’Donnell RW, Marquis DM, et al. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother. 1990;32:62–66
  22. McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: Evidence for the polyclonality of metastases. Cancer. 1981;47:1984–1987
  23. Schwaab T, Heaney JA, Schned AR, et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters. J Urol. 2000;163:1322–1327
  24. Schwaab T, Tretter CP, Gibson JJ, et al. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J Urol. 2004;171:1036–1042
  25. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet. 2004;363:594–599
  26. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer. 1996;77:2560–2566
  27. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539–3543
  28. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997;57:1537–1546
  29. Antonia SJ, Seigne J, Diaz J, et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002;167:1995–2000
  30. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci U S A. 1999;96:2268–2273
  31. Wittig B, Marten A, Dorbic T, et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial. Hum Gene Ther. 2001;12:267–278
  32. Pizza G, De Vinci C, Lo Conte G, et al. Allogeneic gene-modified tumour cells in metastatic kidney cancer (Report II). Folia Biol (Praha). 2004;50:175–183
  33. Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol Ther. 2004;10:799–816
  34. Moiseyenko VM, Danilov AO, Baldueva IA, et al. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: Miscellaneous tumors. Ann Oncol. 2005;16:162–168
  35. Kundig TM, Bachmann MF, Oehen S, et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A. 1996;93:9716–9723
  36. Walzer T, Dalod M, Robbins SH, et al. Natural-killer cells and dendritic cells: “l’union fait la force”. Blood. 2005;106:2252–2258
  37. MacPherson G, Kushnir N, Wykes M. Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev. 1999;172:325–334
  38. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004;53:64–72
  39. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245–273
  40. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109–1118
  41. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997;70:706–715
  42. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251–263
  43. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004;10:4699–4708
  44. Höltl L, Rieser C, Papesh C. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161:777–782
  45. Höltl L, Ramoner R, Zelle-Rieser C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother. 2005;54:663–670
  46. Berd D, Maguire HC, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. 1984;44:5439–5443
  47. Livingston PO, Cunningham-Rundles S, Marfleet G, et al. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod. 1987;6:392–403
  48. Marten A, Renoth S, Heinicke T, et al. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003;14:483–494
  49. Heiser A, Maurice MA, Yancey DR, et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primaryand metastatic tumors. Cancer Res. 2001;61:3388–3393
  50. Heiser A, Maurice MA, Yancey DR, et al. Induction of polyclonal prostate cancer specific cytotoxic T lymphocytes using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953–2960
  51. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63:2127–2133
  52. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93:4309–4317
  53. Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother. 2006;55:63–67
  54. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278:117–120
  55. Yedavelli SP, Guo L, Daou ME, et al. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med. 1999;4:243–248
  56. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol. 2005;6:593–599
  57. Li Z, Qiao Y, Liu B, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res. 2005;11:4460–4468
  58. Achtar MS, Ibrahim RA, Herrin VE, et al. Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. J Clin Oncol. 2004;22:185S;(abstr 2589)
  59. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85:865–870
  60. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999;59:5554–5559
  61. Kim JV, Latouche JB, Riviere I, et al. The ABCs of artificial antigen presentation. Nat Biotechnol. 2004;22:403–410
  62. Oelke M, Krueger C, Giuntoli RL, et al. Artificial antigen-presenting cells: Artificial solutions for real diseases. Trends Mol Med. 2005;11:412–420
  63. Garlie NK, LeFever AV, Siebenlist RE, et al. T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother. 1999;22:336–345
  64. Senju S, Hirata S, Matsuyoshi H, et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood. 2003;101:3501–3508
  65. Fairchild PJ, Brook FA, Gardner RL, et al. Directed differentiation of dendritic cells from mouse embryonic stem cells. Curr Biol. 2000;10:1515–1518
  66. Slukvin , Vodyanik MA, Thomson JA, et al. Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway. II J Immunol. 2006;176:2924–2932
  67. Loyer V, Fontaine P, Pion S, et al. The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol. 1999;163:6462–6467
  68. Fukuma D, Matsuyoshi H, Hirata S, et al. Cancer prevention with semi-allogeneic ES cell-derived dendritic cells. Biochem Biophys Res Commun. 2005;335:5–13
  69. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species. J Leukoc Biol. 2003;74:186–196
  70. De Santo C, Serafini P, Marigo I, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A. 2005;102:4185–4190
  71. Bronte V, Serafini P, Mazzoni A, et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24:302–306
  72. Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172:989–999
  73. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med. 2001;193:F41–F46
  74. Shevach EM, McHugh RS, Piccirillo CA, et al. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001;182:58–67
  75. Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272–4276
  76. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–949
  77. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999;59:3128–3133
  78. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211–5218
  79. LeMaistre CF, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. 1992;79:2547–2554
  80. Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. Cancer Chemother Biol Response Modif. 2002;20:301–313
  81. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated anti-tumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623–3633
  82. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med. 2004;10:887–892
  83. Scharfe T, Muller S, Riedmiller H, et al. Immunotherapy of metastasizing renal cell carcinoma (Results of a multicentered trial). Urol Int. 1989;44:1–4
  84. Zhou X, Jun do Y, Thomas AM, et al. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res. 2005;65:1079–1088
  85. Höltl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res. 2002;8:3369–3376
  86. Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: Preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother. 2002;51:637–644
  87. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A phase 1 study. J Immunother. 2002;25:500–508
  88. Gitlitz BJ, Belldegrun AS, Zisman A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003;26:412–419
  89. Arroyo JC, Gabilondo F, Llorente L, et al. Immune response induced in vitro by CD16− and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol. 2004;24:86–96
  90. Pandha H. Integrative tumor board: metastatic renal cell carcinoma: Medical oncology (II). Integr Cancer Ther. 2004;3:29–34
  91. Barbuto JA, Ensina LF, Neves AR, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother. 2004;53:1111–1118
  92. Amato R, Murray L, Wood L, et al. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein–peptide complex–96 (HSPP-96) vaccine. J Clin Oncol. 1999;17S:1278;(abstr)
  93. Amato R, Wood L, Savary C, et al. Patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex (HSPPC-96) with or without interleukin-2 (IL-2). J Clin Oncol. 2000;18S:1782;(abstr)
  94. Assikis VJ, Daliani D, Pagliaro L, et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2003;21S:1552;(abstr)
  95. Wood CG, Escudier B, Gorelov S, et al. A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC)—A preliminary report. J Clin Oncol. 2004;22:192S;(abstr)

 Supported in part by grants from the National Cancer Institute (RO1 CA93910, R21 CA098446, RO1 CA89102), and the National Center for Research Resources, (MO1-RR-30), General Clinical Research Centers Program.

PII: S0093-7754(06)00277-6

doi: 10.1053/j.seminoncol.2006.06.011

Seminars in Oncology
Volume 33, Issue 5 , Pages 614-624 , October 2006

Article Tools